专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007106882A2 RECOMBINANT MONONEGAVIRAL VIRUS VECTORS 审中-公开
标题翻译：重组单核病毒病毒载体
公开(公告)号：WO2007106882A2
公开(公告)日：2007-09-20
申请号：PCT/US2007/064046
申请日：2007-03-15
申请人： INTERVET INTERNATIONAL B.V. , ROMER-OBERDORFER, Angela , VEITS, Jutta , MEBATSION, Teshome
发明人： ROMER-OBERDORFER, Angela , VEITS, Jutta , MEBATSION, Teshome
IPC分类号： A61K39/00
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5256 , A61K2039/543 , A61K2039/70 , C12N15/86 , C12N2740/15034 , C12N2760/00043 , C12N2760/16134 , C12N2760/18134 , C12N2760/18143 , C12N2760/20143
摘要： The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.
摘要翻译：本发明涉及包含MV病毒基因的非编码区侧翼的外源基因的重组单酮黑病毒（MV）载体。

2. 发明申请

WO2003046506A2 ATTENUATED RABIES VIRUS WITH NUCLEOPROTEIN MUTATION AT THE PHOSPHORYLATION SITE FOR VACCINATION AGAINST RABIES AND GENE THERAPY IN THE CNS 审中-公开
标题翻译：在中枢神经系统的抗病毒和基因治疗用于疫苗接种的细胞培养基中具有核糖体突变的衰减的病毒性病毒
公开(公告)号：WO2003046506A2
公开(公告)日：2003-06-05
申请号：PCT/US2002/023108
申请日：2002-07-22
申请人： THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人： FU, Zhen, Fang
IPC分类号： G01N
CPC分类号： C12N7/00 , A61K39/12 , A61K39/205 , A61K48/00 , A61K2039/5254 , C07K14/005 , C12N15/86 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , C12N2760/20161
摘要： A mutant virus is provided which contains a mutation at a phosphorylation site in one or more of the proteins of the virus, which mutation causes the virus to be attenuated, and therefore, an improved vaccine composition can be produced therewith. The invention also relates to vaccine compositions which contain the mutant virus, as well as to methods of inducing an immune response, and of protecting mammals from infection by rabies virus. Also included in the invention are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or even overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells in which viral production is optimized, as well as vaccine compositions including the viral proteins, either alone or in combination with the intact virus, and to methods of inducing an immune response or protecting a mammal from infection, using the same. Also included in the invention are vectors suitable for delivering a gene to a cell of a human or animal, as well methods of delivery thereof.
摘要翻译：提供了突变病毒，其在病毒的一种或多种蛋白质中的磷酸化位点处含有突变，该突变导致病毒减毒，因此可以用其产生改进的疫苗组合物。本发明还涉及含有突变病毒的疫苗组合物，以及诱导免疫应答的方法，以及保护哺乳动物不被狂犬病病毒感染。本发明还包括产生突变病毒和突变病毒蛋白质的方法，包括在宿主细胞中产生突变病毒，所述宿主细胞产生甚至过度产生突变病毒蛋白质的野生型对应物，其补充其他病毒蛋白质，使得优化突变病毒颗粒的生产。本发明还包括其中优化病毒生产的那些宿主细胞以及包含病毒蛋白的疫苗组合物，其单独或与完整病毒组合，以及诱导免疫应答或保护哺乳动物感染的方法，使用一样。本发明还包括适合将基因递送至人或动物的细胞的载体，以及其递送方法。

3. 发明申请

WO2007070678A2 RABIES VACCINE 审中-公开
公开(公告)号：WO2007070678A2
公开(公告)日：2007-06-21
申请号：PCT/US2006/047921
申请日：2006-12-14
申请人： THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. , FU, Zhen, F.
发明人： FU, Zhen, F.
IPC分类号： A61K39/205
CPC分类号： A61K39/205 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/55522 , C12N7/00 , C12N2760/20134 , C12N2760/20143 , C12N2760/20161
摘要： An attenuated rabies virus for use as a live vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the live vaccine.
摘要翻译：用作活疫苗的减毒狂犬病病毒。减毒的狂犬病病毒表达了在施用活疫苗时增强免疫应答的免疫因子。

4. 发明申请

WO2006078272A2 RHABDOVIRAL N-FUSION PROTEINS AS CARRIER FOR FOREIGN ANTIGENS 审中-公开
标题翻译： RHABDOVIRAL N-FUSION蛋白作为外源抗体携带者
公开(公告)号：WO2006078272A2
公开(公告)日：2006-07-27
申请号：PCT/US2005/013298
申请日：2005-04-19
申请人： THOMAS JEFFERSON UNIVERSITY , SCHNELL, Matthias , DIETZSCHOLD, Bernhard
发明人： SCHNELL, Matthias , DIETZSCHOLD, Bernhard
IPC分类号： A61K39/205
CPC分类号： C07K14/005 , A61K39/00 , A61K39/07 , A61K39/12 , A61K39/205 , A61K39/385 , A61K2039/6075 , C07K2319/00 , C07K2319/40 , C07K2319/55 , C07K2319/60 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , Y02A50/472
摘要： Rabies virus (RV) nucleoprotein (N) tightly encapsidates the genomic and antigenomic RNA thereby forming the ribonucleoprotein (RNP) complex. Antigens presented in a rigid and repetitive organization are sufficient to activate B cells to proliferate. In addition to the repetitive organization, it has been shown that RV N protein induces potent T-helper responses resulting in long-lasting and strong humoral immune responses against RV. The possibility to directly manipulate the genome of RV allows us to examine whether the immunogenicity of foreign antigens can be enhanced via incorporation into the RNP structure. A recombinant RV expressing an RV N-green fluorescent protein (GFP) fusion protein. The chimeric N-GFP fusion protein was efficiently expressed and incorporated into RV RNP and virions. Moreover, the recombinant RNP induces a strong humoral immune response against GFP in mice. In contrast, mice inoculated with GFP alone or a combination of wild-type RV RNPs and GFP did not trigger any GFP-specific humoral responses using the same immunization schedule. These results indicate the usefulness of RV-based vectors as killed vaccines against other infectious diseases.
摘要翻译：狂犬病病毒（RV）核蛋白（N）紧密地包裹基因组和反基因组RNA，从而形成核糖核蛋白（RNP）复合物。呈现在刚性和重复组织中的抗原足以激活B细胞增殖。除了重复组织之外，已经显示RVN蛋白诱导有效的T辅助反应，导致针对RV的持久和强烈的体液免疫应答。直接操纵RV基因组的可能性使得我们能够检查外源抗原的免疫原性是否可以通过纳入RNP结构来增强。表达RVN-绿色荧光蛋白（GFP）融合蛋白的重组RV。嵌合的N-GFP融合蛋白被有效表达并并入RV RNP和病毒粒子中。此外，重组RNP在小鼠中诱导针对GFP的强烈的体液免疫应答。相比之下，用GFP单独接种的小鼠或野生型RV RNP和GFP的组合的小鼠不使用相同的免疫程序触发任何GFP特异性体液应答。这些结果表明基于RV的载体作为针对其他感染性疾病的灭活疫苗的有用性。

5. 发明申请

WO0170932A2 GENETICALLY ENGINEERED RABIES RECOMBINANT VACCINE FOR IMMUNIZATION OF STRAY DOGS AND WILDLIFE 审中-公开
标题翻译：遗传工程用RABES重组疫苗，用于免疫犬和野生动物
公开(公告)号：WO0170932A2
公开(公告)日：2001-09-27
申请号：PCT/US0109529
申请日：2001-03-23
申请人： UNIV JEFFERSON
发明人： DIETZSCHOLD BERNHARD , HOOPER D CRAIG , SCHNELL MATTHIAS
IPC分类号： A61K39/205 , C07K14/145 , C12N7/04 , C12N15/86 , C12N
CPC分类号： C07K14/005 , A61K39/12 , A61K39/205 , A61K2039/5254 , A61K2039/5256 , A61K2039/542 , A61K2039/552 , A61K2039/55516 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , C12N2760/20145 , C12N2760/20161 , C12N2810/6081
摘要： Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity agains rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.
摘要翻译：使用反向遗传学产生活的，减毒的重组狂犬病病毒疫苗，以将使狂犬病病毒非致病性的抗原决定簇与负责引发有效的抗狂犬病免疫应答的决定簇结合。这些疫苗不影响病毒的抗原性，因此不影响免疫原性。本发明还涉及表达促细胞凋亡蛋白（例如细胞色素c）的重组狂犬病毒疫苗，以增加诱导细胞凋亡的能力，从而再次增强狂犬病的保护性免疫力。这种新一代的狂犬病毒疫苗代表了一种安全有效的方法来消灭野生动物，随后人类和家畜的狂犬病。

6. 发明申请

WO2012106490A1 MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUSES 审中-公开
标题翻译：用于RABIES病毒和FILOVIRUSUS的多种疫苗
公开(公告)号：WO2012106490A1
公开(公告)日：2012-08-09
申请号：PCT/US2012/023575
申请日：2012-02-02
申请人： THE GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES , BLANEY, Joseph, E. , PARAGAS, Jason , JAHRLING, Peter , JOHNSON, Reed , SCHNELL, Mathias
发明人： BLANEY, Joseph, E. , PARAGAS, Jason , JAHRLING, Peter , JOHNSON, Reed , SCHNELL, Mathias
IPC分类号： C12N7/00 , A61K39/12 , C12N15/86 , A61K39/295
CPC分类号： A61K45/06 , A61K39/08 , A61K39/12 , A61K39/205 , A61K2039/5252 , A61K2039/5254 , A61K2039/5256 , A61K2039/543 , A61K2039/70 , C12N7/00 , C12N15/86 , C12N2760/14134 , C12N2760/14234 , C12N2760/20043 , C12N2760/20134 , C12N2760/20143
摘要： The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compostions comprising the vaccine vectors.
摘要翻译：本发明提供用于诱导免疫应答的方法和组合物，该免疫应答赋予双重保护以抵抗狂犬病病毒和弗洛伊病毒中的任一种或两者的感染，和/或可用于治疗性地用于狂犬病病毒和/或病毒性病毒的现有感染以治疗其至少一种症状和/或中和或清除感染剂。特别地，本发明提供了包含编码至少一种病毒糖蛋白或其免疫原性片段的核苷酸序列的重组狂犬病病毒载体，以及包含疫苗载体的药物组合物。

7. 发明申请

WO2011163446A3 PAN-LYSSAVIRUS VACCINES AGAINST RABIES 审中-公开
标题翻译： PAN-LYSSAVIRUS疫苗对兔子
公开(公告)号：WO2011163446A3
公开(公告)日：2012-04-05
申请号：PCT/US2011041579
申请日：2011-06-23
申请人： US GOV HEALTH & HUMAN SERV , WU XIANFU , RUPPRECHT CHARLES E , KUZMIN IVAN V
发明人： WU XIANFU , RUPPRECHT CHARLES E , KUZMIN IVAN V
IPC分类号： C12N15/47 , A61K39/205 , C12N15/63
CPC分类号： A61K39/205 , A61K39/12 , A61K2039/5256 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2760/20121 , C12N2760/20122 , C12N2760/20134 , C12N2760/20143 , C12N2760/20152 , C12N2800/50
摘要： Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.
摘要翻译：本文描述的是编码狂犬病病毒糖蛋白的重组狂犬病病毒和来自另一种狂犬病病毒如莫科拉病毒，拉各斯蝙蝠病毒和/或西白种蝙蝠病毒的至少一种异源糖蛋白。在具体实施方案中，重组狂犬病病毒包括两种或三种异源性淋巴细胞病毒糖蛋白。所公开的重组狂犬病病毒可用作泛菌丝炎病毒疫苗，以提供针对引起狂犬病的狂犬病病毒的保护。

8. 发明申请

WO2007106882A3 RECOMBINANT MONONEGAVIRAL VIRUS VECTORS 审中-公开
标题翻译：重组单核病毒病毒载体
公开(公告)号：WO2007106882A3
公开(公告)日：2008-01-17
申请号：PCT/US2007064046
申请日：2007-03-15
申请人： INTERVET INT BV , ROMER-OBERDORFER ANGELA , VEITS JUTTA , MEBATSION TESHOME
发明人： ROMER-OBERDORFER ANGELA , VEITS JUTTA , MEBATSION TESHOME
IPC分类号： C12N15/45 , A61K35/76
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5256 , A61K2039/543 , A61K2039/70 , C12N15/86 , C12N2740/15034 , C12N2760/00043 , C12N2760/16134 , C12N2760/18134 , C12N2760/18143 , C12N2760/20143
摘要： The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.
摘要翻译：本发明涉及包含MV病毒基因的非编码区侧翼的外源基因的重组单酮黑病毒（MV）载体。

9. 发明申请

WO2007047459A8 RABIES VIRUS VECTOR SYSTEMS AND COMPOSITIONS AND METHODS THEREOF 审中-公开
标题翻译：狂犬病病毒载体系统及其组合物和方法
公开(公告)号：WO2007047459A8
公开(公告)日：2007-09-20
申请号：PCT/US2006040134
申请日：2006-10-13
申请人： US GOV HEALTH & HUMAN SERV , RUPPRECHT CHARLES E , WU XIANFU
发明人： RUPPRECHT CHARLES E , WU XIANFU
IPC分类号： C12N15/867
CPC分类号： C12N7/00 , A61K39/12 , A61K39/205 , A61K2039/5254 , C12N15/86 , C12N2760/20134 , C12N2760/20143 , C12N2760/20161
摘要： Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatement of Rabies Virus.
摘要翻译：提供了狂犬病病毒组合物和方法。披露了狂犬病病毒株Evelyn-Rokitnicki-Abelseth（ERA）的全长序列。提供了用于产生重组ERA病毒及其衍生物的反向遗传学系统，以及包含ERA和/或ERA衍生株病毒，核酸和/或蛋白质的组合物。在一些情况下，组合物是可用于狂犬病病毒的暴露前或暴露后处理的免疫原性组合物。

10. 发明申请

WO02089728A3 RECOMBINANT RHABDOVIRUSES AS LIVE-VIRAL VACCINES 审中-公开
标题翻译：作为活体病毒的重组人RHABDOVIRUSES
公开(公告)号：WO02089728A3
公开(公告)日：2003-07-10
申请号：PCT/US0212637
申请日：2002-04-19
申请人： UNIV JEFFERSON
发明人： SCHNELL MATTHIAS J , POMERANTZ ROGER J
IPC分类号： C07K14/145 , C07K14/155 , C07K14/16 , C07K14/18 , C12N7/04 , C12N15/86 , A61K39/12 , A01N63/00 , A61K39/205 , A61K39/21 , A61K39/29
CPC分类号： C07K14/005 , A61K2039/545 , A61K2039/57 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/24143 , C12N2710/24164 , C12N2740/15022 , C12N2740/16122 , C12N2760/20122 , C12N2760/20143 , C12N2770/24222
摘要： This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologous antigenic polypeptides. The HIV-1 gp160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, up to 1:800, against HIV-1 are detected in the mouse sera. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral-specific immune responses.
摘要翻译：本发明提供用于表达异源病毒抗原性多肽（例如免疫缺陷病毒包膜蛋白或其子部分）的重组，基于复制能力的基于弹状病毒基因毒株的表达载体。插入Rhabdovirus基因组内的另外的转录停止/起始单位以表达异源抗原多肽。 HIV-1 gp160蛋白质是稳定和功能表达的，如通过重组RV感染后的人T细胞系的融合所表明的。用重组的表达HIV-1 gp160的狂犬病病毒接种小鼠，用分离的重组HIV-1 gp120蛋白单次加强后，诱导针对HIV-1包膜蛋白的强烈体液应答。此外，在小鼠血清中检测到针对HIV-1的高达1：800的高中和滴度。表达病毒抗原多肽的这些重组病毒载体提供用于产生病毒特异性免疫应答的有用和有效的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式